ARCHIVES

Highlights of NCDDGs: 3 Drugs on Market, 12 in Development; Advisors Approve Plan to Issue $10.5 Million Contract For Pediatric Preclinical Testing Program

This article is from The Cancer Letter archive.

Vol. 28 No. 44 | November 29, 2002

Download PDF Visit The Full Archive

Related Articles

FDA Approves NDA For Mylan’s Paclitaxel For Ovarian And Breast Cancer Treatment.

July 27, 2001

In Brief: Durant To Retire From ASCO In A Year; Led Society Through Management Change

July 24, 1998

FDA Designates Zometa For Priority Review.

November 30, 2001

NCAB Approves CIS Recompetition, Restructuring

May 17, 1991

NCI Cooperative Group, Cancer Center Trials Listed

July 27, 2007

NCI, EORTC Offer Support For Russian Cancer Researchers

April 14, 1995